Bergen Open Research Archive >
Faculty of Medicine >
Institute of Medicine >
Section for Haematology >
Please use this identifier to cite or link to this item:
http://hdl.handle.net/1956/2620
|
| Title: | Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells |
| Authors: | Wergeland, Line Sjøholt, Gry Haaland, Ingvild Hovland, Randi Bruserud, Øystein Gjertsen, Bjørn Tore |
| Issue Date: | 2007 |
| Publisher: | BioMed Central |
| Citation: | Molecular Cancer, 6:33 |
| Abstract: | Background: Acute myeloid leukemia (AML) cells are characterized by non-mutated TP53, high
levels of Hdm2, and frequent mutation of the Flt3 receptor tyrosine kinase. The juxtamembrane
mutation of FLT3 is the strongest independent marker for disease relapse and is associated with
elevated Bcl-2 protein and p53 hyper-phosphorylation in AML. DNA damage forms the basic
mechanism of cancer cell eradication in current therapy of AML.
Hdm2 and pro-apoptotic Bcl-2 members are among the most intensely induced genes immediately
after chemotherapy and Hdm2 is proposed a role in receptor tyrosine kinase regulation. Thus we
examined the DNA damage related modulation of these proteins in relation to FLT3 mutational
status and induction of apoptosis.
Results: Within one hour after exposure to ionizing radiation (IR), the AML cells (NB4, MV4-11,
HL-60, primary AML cells) showed an increase in Flt3 protein independent of mRNA levels, while
the Hdm2 protein decreased. The FLT3 mutant MV4-11 cells were resistant to IR accompanied by
presence of both Mcl-1 and Hdm2 protein three hours after IR. In contrast, the FLT3 wild type NB4
cells responded to IR with apoptosis and pre-apoptotic Mcl-1 down regulation. Daunorubicin
(DNR) induced continuing down regulation of Hdm2 and Mcl-1 in both cell lines followed by
apoptosis.
Conclusion: Both IR and DNR treatment resulted in concerted protein modulations of Mcl-1,
Hdm2 and Flt3. Cell death induction was associated with persistent attenuation of Mcl-1 and Hdm2.
These observations suggest that defining the pathway(s) modulating Flt3, Hdm2 and Mcl-1 may
propose new strategies to optimize therapy for the relapse prone FLT3 mutated AML patients. |
| URI: | http://dx.doi.org/10.1186/1476-4598-6-33 http://hdl.handle.net/1956/2620 |
| Appears in Collections: | Section for Haematology
|
Items in BORA are protected by copyright, with all rights reserved, unless otherwise indicated.